FAKTOR-OPTIONSSCHEIN - BIONTECH ADR Stock

Certificat

DE000SV1PGM0

Market Closed - Boerse Frankfurt Warrants 15:45:35 2024-05-03 EDT
0.054 EUR +5.88% Intraday chart for FAKTOR-OPTIONSSCHEIN - BIONTECH ADR
Current month+29.27%
1 month-1.85%
Date Price Change Volume
24-05-03 0.053 +3.92% 0
24-05-02 0.051 +24.39% 0
24-04-30 0.041 +5.13% 0
24-04-29 0.039 +11.43% 0
24-04-26 0.035 0.00% 0

Real-time Boerse Frankfurt Warrants

Last update May 03, 2024 at 03:45 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Société Générale Société Générale
WKN SV1PGM
ISINDE000SV1PGM0
Date issued 2023-03-03
Strike- $
Maturity Unlimited
Parity 1 : 1
Emission price 20.84
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 27.66
Lowest since issue 0.031
Spread 0.01
Spread %15.63%

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
86.07 EUR
Average target price
107 EUR
Spread / Average Target
+24.34%
Consensus